NASDAQ:BPMC Blueprint Medicines (BPMC) Stock Price, News & Analysis → Elon Musk: THIS will be bigger than Tesla (From Paradigm Press) (Ad) Free BPMC Stock Alerts $105.55 -0.84 (-0.79%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$103.49▼$106.8650-Day Range$85.18▼$108.7852-Week Range$43.89▼$111.02Volume464,283 shsAverage Volume471,894 shsMarket Capitalization$6.61 billionP/E RatioN/ADividend YieldN/APrice Target$108.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Blueprint Medicines alerts: Email Address Blueprint Medicines MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.63 Rating ScoreUpside/Downside2.3% Upside$108.00 Price TargetShort InterestBearish7.09% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.64Based on 4 Articles This WeekInsider TradingSelling Shares$8.46 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($5.15) to ($2.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.52 out of 5 starsMedical Sector863rd out of 914 stocksPharmaceutical Preparations Industry407th out of 429 stocks 2.3 Analyst's Opinion Consensus RatingBlueprint Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 9 buy ratings, 5 hold ratings, and 1 sell rating.Amount of Analyst CoverageBlueprint Medicines has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Blueprint Medicines' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.09% of the outstanding shares of Blueprint Medicines have been sold short.Short Interest Ratio / Days to CoverBlueprint Medicines has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Blueprint Medicines has recently decreased by 1.77%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldBlueprint Medicines does not currently pay a dividend.Dividend GrowthBlueprint Medicines does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BPMC. Previous Next 2.0 News and Social Media Coverage News SentimentBlueprint Medicines has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Blueprint Medicines this week, compared to 5 articles on an average week.Search Interest3 people have searched for BPMC on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Blueprint Medicines to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Blueprint Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,460,634.00 in company stock.Percentage Held by InsidersOnly 4.21% of the stock of Blueprint Medicines is held by insiders.Read more about Blueprint Medicines' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Blueprint Medicines are expected to grow in the coming year, from ($5.15) to ($2.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Blueprint Medicines is -21.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Blueprint Medicines is -21.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBlueprint Medicines has a P/B Ratio of 49.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Blueprint Medicines' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you must get in now. Don’t delay.See all the details you need here. About Blueprint Medicines Stock (NASDAQ:BPMC)Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.Read More BPMC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BPMC Stock News HeadlinesJune 8, 2024 | insidertrades.comBlueprint Medicines Co. (NASDAQ:BPMC) Insider Sells $420,520.00 in StockJune 5, 2024 | insidertrades.comInsider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) Insider Sells 4,922 Shares of StockJune 5, 2024 | insidertrades.comInsider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) Insider Sells $3,612,378.28 in StockJune 10, 2024 | americanbankingnews.comInsider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) Insider Sells $420,520.00 in StockJune 9, 2024 | americanbankingnews.comBlueprint Medicines (NASDAQ:BPMC) Stock Rating Reaffirmed by JMP SecuritiesMay 30, 2024 | prnewswire.comBlueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)May 26, 2024 | finance.yahoo.comBlueprint Medicines Corporation (BPMC)May 23, 2024 | prnewswire.comBlueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual MeetingMay 21, 2024 | finance.yahoo.comBlueprint Medicines (NASDAQ:BPMC) pulls back 3.5% this week, but still delivers shareholders notable 85% return over 1 yearMay 15, 2024 | msn.comStephens & Co. Initiates Coverage of Blueprint Medicines (BPMC) with Overweight RecommendationMay 14, 2024 | msn.comBlueprint Medicines started at buy by Stephens, citing Ayvakit franchiseMay 14, 2024 | markets.businessinsider.comUnveiling 18 Analyst Insights On Blueprint MedicinesMay 9, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Blueprint Medicines (BPMC)May 7, 2024 | finance.yahoo.comZacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and LigandMay 7, 2024 | msn.comLeerink Partners Upgrades Blueprint Medicines (BPMC)May 6, 2024 | prnewswire.comBlueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 4, 2024 | markets.businessinsider.comSell/High Risk: Cautious Outlook on Blueprint Medicines Amidst Unsustainable Growth FactorsMay 4, 2024 | finance.yahoo.comBlueprint Medicines Corp (BPMC) (Q1 2024) Earnings Call Transcript Highlights: Surpassing ...May 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for Blueprint Medicines on Strong Financials and Clinical Pipeline ProspectsMay 4, 2024 | finance.yahoo.comBlueprint Medicines Corporation (NASDAQ:BPMC) Q1 2024 Earnings Call TranscriptMay 3, 2024 | finance.yahoo.comQ1 2024 Blueprint Medicines Corp Earnings CallMay 2, 2024 | marketwatch.comBlueprint Medicines Shares Hit 52-Week on Strong Ayvakit SalesMay 2, 2024 | msn.comBPMC Stock Earnings: Blueprint Medicines Beats EPS, Beats Revenue for Q1 2024May 2, 2024 | finance.yahoo.comBlueprint Medicines Corp Reports Q1 2024 Earnings, Surpasses Revenue Estimates and Raises ...May 2, 2024 | seekingalpha.comBlueprint Medicines Corporation 2024 Q1 - Results - Earnings Call PresentationSee More Headlines Receive BPMC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today6/15/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BPMC CUSIPN/A CIK1597264 Webwww.blueprintmedicines.com Phone(617) 374-7580FaxN/AEmployees655Year Founded2011Price Target and Rating Average Stock Price Target$108.00 High Stock Price Target$168.00 Low Stock Price Target$63.00 Potential Upside/Downside+2.3%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($4.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-506,980,000.00 Net Margins-102.15% Pretax Margin-101.93% Return on Equity-193.48% Return on Assets-42.98% Debt Debt-to-Equity Ratio0.67 Current Ratio3.76 Quick Ratio3.61 Sales & Book Value Annual Sales$249.38 million Price / Sales26.50 Cash FlowN/A Price / Cash FlowN/A Book Value$2.15 per share Price / Book49.09Miscellaneous Outstanding Shares62,620,000Free Float59,981,000Market Cap$6.61 billion OptionableOptionable Beta0.70 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMs. Kathryn Haviland (Age 48)President, CEO & Director Comp: $1.17MMr. Alexis A. Borisy A.M. (Age 52)Co-Founder & Director Comp: $50kMr. Michael Landsittel (Age 52)Chief Financial Officer Comp: $785.36kMs. Tracey L. McCain Esq. (Age 56)Executive VP, Chief Legal & Compliance Officer and Secretary Comp: $764.9kDr. Fouad Namouni M.D. (Age 55)President of Research & Development Comp: $916.4kMs. Ariel Hurley (Age 50)Senior VP, Finance & Principal Accounting Officer Dr. Christopher K. Murray Ph.D. (Age 60)Senior VP of Technical Operations and Chief Technical Operations & Quality Officer Comp: $338.37kDr. Percy H. Carter M.B.A. (Age 53)Ph.D., Chief Scientific Officer Comp: $761.15kJenna CohenSenior Director & Head of Investor RelationsMs. Debra Durso-Bumpus (Age 54)Chief People Officer More ExecutivesKey CompetitorsForty SevenNASDAQ:FTSVTurning Point TherapeuticsNASDAQ:TPTXCelldex TherapeuticsNASDAQ:CLDXDeciphera PharmaceuticalsNASDAQ:DCPHSchrödingerNASDAQ:SDGRView All CompetitorsInsiders & InstitutionsNBW Capital LLCSold 1,791 shares on 6/13/2024Ownership: 0.081%Percy H CarterSold 4,000 sharesTotal: $420,520.00 ($105.13/share)DekaBank Deutsche GirozentraleBought 733 shares on 6/4/2024Ownership: 0.041%L. Becker HewesSold 4,922 sharesTotal: $523,848.46 ($106.43/share)L. Becker HewesSold 34,108 sharesTotal: $3.61 M ($105.91/share)View All Insider TransactionsView All Institutional Transactions BPMC Stock Analysis - Frequently Asked Questions Should I buy or sell Blueprint Medicines stock right now? 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last year. There are currently 1 sell rating, 5 hold ratings, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BPMC shares. View BPMC analyst ratings or view top-rated stocks. What is Blueprint Medicines' stock price target for 2024? 16 analysts have issued 12 month price objectives for Blueprint Medicines' shares. Their BPMC share price targets range from $63.00 to $168.00. On average, they anticipate the company's share price to reach $108.00 in the next twelve months. This suggests a possible upside of 2.3% from the stock's current price. View analysts price targets for BPMC or view top-rated stocks among Wall Street analysts. How have BPMC shares performed in 2024? Blueprint Medicines' stock was trading at $92.24 on January 1st, 2024. Since then, BPMC stock has increased by 14.4% and is now trading at $105.55. View the best growth stocks for 2024 here. When is Blueprint Medicines' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our BPMC earnings forecast. How were Blueprint Medicines' earnings last quarter? Blueprint Medicines Co. (NASDAQ:BPMC) issued its earnings results on Thursday, May, 2nd. The biotechnology company reported ($1.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.64) by $0.32. The biotechnology company had revenue of $96.12 million for the quarter, compared to analyst estimates of $82.58 million. Blueprint Medicines had a negative trailing twelve-month return on equity of 193.48% and a negative net margin of 102.15%. What ETFs hold Blueprint Medicines' stock? ETFs with the largest weight of Blueprint Medicines (NASDAQ:BPMC) stock in their portfolio include Tema Oncology ETF (CANC), Invesco Biotechnology & Genome ETF (PBE), WisdomTree BioRevolution Fund (WDNA), Virtus LifeSci Biotech Products ETF (BBP), Harbor Corporate Culture Small Cap ETF (HAPS), BlackRock Future Health ETF (BMED), Range Cancer Therapeutics ETF (CNCR) and Loncar China Biopharma ETF (CHNA). What is Kate Haviland's approval rating as Blueprint Medicines' CEO? 16 employees have rated Blueprint Medicines Chief Executive Officer Kate Haviland on Glassdoor.com. Kate Haviland has an approval rating of 100% among the company's employees. This puts Kate Haviland in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at Blueprint Medicines to a friend. What other stocks do shareholders of Blueprint Medicines own? Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), QUALCOMM (QCOM), Amarin (AMRN), CRISPR Therapeutics (CRSP) and Nektar Therapeutics (NKTR). When did Blueprint Medicines IPO? Blueprint Medicines (BPMC) raised $115 million in an initial public offering (IPO) on Thursday, April 30th 2015. The company issued 7,200,000 shares at $15.00-$17.00 per share. Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are Blueprint Medicines' major shareholders? Blueprint Medicines' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (10.31%), Price T Rowe Associates Inc. MD (10.21%), William Blair Investment Management LLC (2.79%), Lord Abbett & CO. LLC (2.15%), Hood River Capital Management LLC (0.77%) and Jane Street Group LLC (0.00%). Insiders that own company stock include Ariel Hurley, Christina Rossi, Christopher K Murray, Debra Durso-Bumpus, Fouad Namouni, George Demetri, Jeffrey W Albers, Kate Haviland, L Becker Hewes, Mark Alan Goldberg, Michael Landsittel, Percy H Carter and Tracey L Mccain. View institutional ownership trends. How do I buy shares of Blueprint Medicines? Shares of BPMC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BPMC) was last updated on 6/16/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredBiden out June 13; replacement chosen?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Blueprint Medicines Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Blueprint Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.